Literature DB >> 11722406

Prognostic significance of risk group stratification in elderly patients with acute myeloid leukaemia.

A Wahlin1, B Markevärn, I Golovleva, M Nilsson.   

Abstract

Prognostic factors were studied in a series of 211 acute myeloid leukaemia (AML) patients over 60 years of age, treated at a single centre. The patients were allocated into three risk groups based on cytogenetics, occurrence of antecedent haematological disorder and leucocyte count. Only 3% had low-risk features, 39% had intermediate- and 58% had adverse-risk features. Complete remission (CR) was achieved in 43% of all patients. In multivariate analyses, the number of cycles needed to achieve CR and the risk group were significantly associated with the duration of CR. Median survival time for the entire cohort of patients was only 107 d. Advanced age, low induction treatment intensity, treatment during earlier years and adverse-risk group were associated with shorter overall survival times. Risk group classification may help selection of elderly patients with a good chance of benefiting from intensive treatment to actually receive such treatment, while sparing others with a low probability of survival benefit from toxic treatment. Low intensity induction treatment reduces the chance of obtaining complete remission, produces inferior survival times and should consequently be avoided when the aim is to obtain complete remission. In elderly AML patients, introducing age and re-evaluation of intermediate and good prognosis patients regarding response to induction treatment may improve the risk group classification.

Entities:  

Mesh:

Year:  2001        PMID: 11722406     DOI: 10.1046/j.1365-2141.2001.03043.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  17 in total

1.  Intensive induction is effective in selected octogenarian acute myeloid leukemia patients: prognostic significance of karyotype and selected molecular markers used in the European LeukemiaNet classification.

Authors:  Meir Wetzler; Krzysztof Mrózek; Jessica Kohlschmidt; Hervé Dombret; Hartmut Döhner; Sylvain Pilorge; Utz Krug; Andrew J Carroll; Richard A Larson; Guido Marcucci; Wolfgang Hiddemann; Thomas Büchner; Clara D Bloomfield
Journal:  Haematologica       Date:  2013-10-04       Impact factor: 9.941

2.  Prior hypomethylating agent use lacks impact on clinical outcome in patients with secondary acute myeloid leukemia arising from myelodysplastic syndromes treated with standard induction chemotherapy.

Authors:  Salih Subari; Firas Baidoun; Muhanad Hreh; Mrinal Patnaik; Shahrukh Hashmi; Michelle Elliott; William Hogan; Mark Litzow; Aref Al-Kali
Journal:  Int J Hematol       Date:  2016-01-18       Impact factor: 2.490

3.  Combined molecular and clinical prognostic index for relapse and survival in cytogenetically normal acute myeloid leukemia.

Authors:  Friederike Pastore; Annika Dufour; Tobias Benthaus; Klaus H Metzeler; Kati S Maharry; Stephanie Schneider; Bianka Ksienzyk; Gudrun Mellert; Evelyn Zellmeier; Purvi M Kakadia; Michael Unterhalt; Michaela Feuring-Buske; Christian Buske; Jan Braess; Maria Cristina Sauerland; Achim Heinecke; Utz Krug; Wolfgang E Berdel; Thomas Buechner; Bernhard Woermann; Wolfgang Hiddemann; Stefan K Bohlander; Guido Marcucci; Karsten Spiekermann; Clara D Bloomfield; Eva Hoster
Journal:  J Clin Oncol       Date:  2014-04-07       Impact factor: 44.544

4.  Geriatric assessment in older patients with acute myeloid leukemia: a retrospective study of associated treatment and outcomes.

Authors:  Alexander E Sherman; Gabriela Motyckova; K Rebecca Fega; Daniel J Deangelo; Gregory A Abel; David Steensma; Martha Wadleigh; Richard M Stone; Jane A Driver
Journal:  Leuk Res       Date:  2013-06-06       Impact factor: 3.156

Review 5.  Prophylactic Measures During Induction for Acute Myeloid Leukemia.

Authors:  Matthew W McCarthy; Thomas J Walsh
Journal:  Curr Oncol Rep       Date:  2017-03       Impact factor: 5.075

6.  Treating octogenarian and nonagenarian acute myeloid leukemia patients--predictive prognostic models.

Authors:  Antoine J Harb; Wei Tan; Gregory E Wilding; LaurieAnn Ford; Sheila N J Sait; AnneMarie W Block; Maurice Barcos; Paul K Wallace; Eunice S Wang; Meir Wetzler
Journal:  Cancer       Date:  2009-06-01       Impact factor: 6.860

7.  American Society of Hematology 2020 guidelines for treating newly diagnosed acute myeloid leukemia in older adults.

Authors:  Mikkael A Sekeres; Gordon Guyatt; Gregory Abel; Shabbir Alibhai; Jessica K Altman; Rena Buckstein; Hannah Choe; Pinkal Desai; Harry Erba; Christopher S Hourigan; Thomas W LeBlanc; Mark Litzow; Janet MacEachern; Laura C Michaelis; Sudipto Mukherjee; Kristen O'Dwyer; Ashley Rosko; Richard Stone; Arnav Agarwal; L E Colunga-Lozano; Yaping Chang; QiuKui Hao; Romina Brignardello-Petersen
Journal:  Blood Adv       Date:  2020-08-11

Review 8.  The evolving landscape in the therapy of acute myeloid leukemia.

Authors:  Grace L Peloquin; Yi-Bin Chen; Amir T Fathi
Journal:  Protein Cell       Date:  2013-08-27       Impact factor: 14.870

9.  Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461.

Authors:  Sherif S Farag; Kellie J Archer; Krzysztof Mrózek; Amy S Ruppert; Andrew J Carroll; James W Vardiman; Mark J Pettenati; Maria R Baer; Mazin B Qumsiyeh; Prasad R Koduru; Yi Ning; Robert J Mayer; Richard M Stone; Richard A Larson; Clara D Bloomfield
Journal:  Blood       Date:  2006-03-07       Impact factor: 22.113

10.  Multiple myeloma in the very old: an IASIA conference report.

Authors:  Sascha A Tuchman; Gary R Shapiro; William B Ershler; Ashraf Badros; Harvey J Cohen; Angela Dispenzieri; Irene Q Flores; Bindu Kanapuru; Donald Jurivich; Dan L Longo; Ali Nourbakhsh; Antonio Palumbo; Jeremy Walston; Jerome W Yates
Journal:  J Natl Cancer Inst       Date:  2014-04-03       Impact factor: 13.506

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.